Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The antitumor activity of teniposide (VM26) was investigated in Lewis lung carcinoma (3LL) of the mouse after a single dose of 20 mg/kg iv (given 8 or 14 days after tumor transplant) or after three doses of 6.5 mg/kg iv (given on Days 8, 11, and 14 after tumor transplant) (total dose, 19.5 mg/kg). The single dose resulted in only 25% primary tumor reduction but had marked antimetastatic activity. The repeated doses (6.5 mg/kg x 3) were much more effective, with 85% primary tumor reduction and the apparent disappearance of all metastatic deposits. The pharmacokinetics of VM26 was investigated in 3LL-bearing mice by a high-performance liquid chromatographic assay. At both of the above doses VM26 disappeared from mouse plasma biphasically, with an elimination half-life of about 70 mins. The concentrations in metastases were higher than in primary tumor, where very low levels were found. The highest VM26 levels were found in liver, small intestine, and kidney, and the lowest levels were found in the brain. Excretion of VM26 in urine amounted to <5% of the dose.

Original languageEnglish
Pages (from-to)555-559
Number of pages5
JournalCancer Treatment Reports
Volume67
Issue number6
Publication statusPublished - 1983

Fingerprint

Teniposide
Lewis Lung Carcinoma
Pharmacokinetics
Neoplasms
Transplants
Small Intestine
Half-Life
Urine
Neoplasm Metastasis
Kidney
Liver
Brain

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice. / Broggini, M.; Colombo, T.; D'Incalci, M.

In: Cancer Treatment Reports, Vol. 67, No. 6, 1983, p. 555-559.

Research output: Contribution to journalArticle

@article{6a1912ddab454338a3898f06d560e7c3,
title = "Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice",
abstract = "The antitumor activity of teniposide (VM26) was investigated in Lewis lung carcinoma (3LL) of the mouse after a single dose of 20 mg/kg iv (given 8 or 14 days after tumor transplant) or after three doses of 6.5 mg/kg iv (given on Days 8, 11, and 14 after tumor transplant) (total dose, 19.5 mg/kg). The single dose resulted in only 25{\%} primary tumor reduction but had marked antimetastatic activity. The repeated doses (6.5 mg/kg x 3) were much more effective, with 85{\%} primary tumor reduction and the apparent disappearance of all metastatic deposits. The pharmacokinetics of VM26 was investigated in 3LL-bearing mice by a high-performance liquid chromatographic assay. At both of the above doses VM26 disappeared from mouse plasma biphasically, with an elimination half-life of about 70 mins. The concentrations in metastases were higher than in primary tumor, where very low levels were found. The highest VM26 levels were found in liver, small intestine, and kidney, and the lowest levels were found in the brain. Excretion of VM26 in urine amounted to <5{\%} of the dose.",
author = "M. Broggini and T. Colombo and M. D'Incalci",
year = "1983",
language = "English",
volume = "67",
pages = "555--559",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "6",

}

TY - JOUR

T1 - Activity and pharmacokinetics of teniposide in Lewis lung carcinoma-bearing mice

AU - Broggini, M.

AU - Colombo, T.

AU - D'Incalci, M.

PY - 1983

Y1 - 1983

N2 - The antitumor activity of teniposide (VM26) was investigated in Lewis lung carcinoma (3LL) of the mouse after a single dose of 20 mg/kg iv (given 8 or 14 days after tumor transplant) or after three doses of 6.5 mg/kg iv (given on Days 8, 11, and 14 after tumor transplant) (total dose, 19.5 mg/kg). The single dose resulted in only 25% primary tumor reduction but had marked antimetastatic activity. The repeated doses (6.5 mg/kg x 3) were much more effective, with 85% primary tumor reduction and the apparent disappearance of all metastatic deposits. The pharmacokinetics of VM26 was investigated in 3LL-bearing mice by a high-performance liquid chromatographic assay. At both of the above doses VM26 disappeared from mouse plasma biphasically, with an elimination half-life of about 70 mins. The concentrations in metastases were higher than in primary tumor, where very low levels were found. The highest VM26 levels were found in liver, small intestine, and kidney, and the lowest levels were found in the brain. Excretion of VM26 in urine amounted to <5% of the dose.

AB - The antitumor activity of teniposide (VM26) was investigated in Lewis lung carcinoma (3LL) of the mouse after a single dose of 20 mg/kg iv (given 8 or 14 days after tumor transplant) or after three doses of 6.5 mg/kg iv (given on Days 8, 11, and 14 after tumor transplant) (total dose, 19.5 mg/kg). The single dose resulted in only 25% primary tumor reduction but had marked antimetastatic activity. The repeated doses (6.5 mg/kg x 3) were much more effective, with 85% primary tumor reduction and the apparent disappearance of all metastatic deposits. The pharmacokinetics of VM26 was investigated in 3LL-bearing mice by a high-performance liquid chromatographic assay. At both of the above doses VM26 disappeared from mouse plasma biphasically, with an elimination half-life of about 70 mins. The concentrations in metastases were higher than in primary tumor, where very low levels were found. The highest VM26 levels were found in liver, small intestine, and kidney, and the lowest levels were found in the brain. Excretion of VM26 in urine amounted to <5% of the dose.

UR - http://www.scopus.com/inward/record.url?scp=0020622256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020622256&partnerID=8YFLogxK

M3 - Article

VL - 67

SP - 555

EP - 559

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 6

ER -